Molecular Genetics of Alzheimer's Disease
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Genetics".
Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 1895
Special Issue Editors
Interests: age-related neurodegenerative diseases; neurogenetics; functional genomics; regulation of gene expression; precision medicine and ‘next generation’ gene therapy approaches for Alzheimer’s-Parkinson’s
Special Issues, Collections and Topics in MDPI journals
Interests: gene therapy; neurodegenerative diseases; gene regulation; epigenetic
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer's disease (AD) has a very strong genetic component, with heredity estimated at between 58 and 79%. The vast majority of AD cases are late-onset (LOAD) ‘sporadic’ forms, with no obvious familial inheritance pattern. Thirty years ago, the first and strongest genetic risk factor of LOAD—the e4 allele of the apolipoprotein E gene (APOE e4)—was discovered by linkage analysis of pedigrees. Advances in genetic and genomic technologies over the following years have greatly enhanced our knowledge concerning the genetic underpinning LOAD, and we are now aware of numerous regions in the genome that confer risk for LOAD. Functional genomic studies, including emerging integrative approaches and single-cell techniques, show promise in identifying the specific target genes through which LOAD risk loci act. However, the genetic architecture underlying LOAD is far from being fully understood. Decoding the genetic architecture of LOAD is an essential part of efforts to understand the pathophysiological processes of the disease, and will yield translational knowledge that is crucial for the development of new therapeutic targets and biomarkers for LOAD.
Original manuscripts and reviews that discuss any aspect of the genetic architecture of LOAD, related mechanistic insights and translational implications are welcome.
Prof. Dr. Ornit Chiba-Falek
Dr. Boris Kantor
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s Disease
- polygenic risk score
- genome wide association studies
- transcriptomic
- epigenomic
